NEW YORK, Aug. 30 – Bruker Daltonics and Thermo Finnigan have reached a settlement agreement in their multi-year, international patent dispute over the companies’ ion trap mass spectrometry technologies, the companies announced Thursday.

As part of the agreement, both companies have agreed to dismiss all pending suits throughout the US and Europe and waive all damages related to the disputes. The agreement also provides a framework of licensing and arbitration for potential future patent disagreements between the companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.